HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Shinya Minatoguchi Selected Research

miglitol (Glyset)

11/2019The intestine responds to heart failure by enhanced mitochondrial fusion through glucagon-like peptide-1 signalling.
9/2011Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits.
10/2005The anti-diabetic drug miglitol is protective against anginal ischaemia through a mechanism independent of regional myocardial blood flow in the dog.
7/2004Antidiabetic drug miglitol inhibits myocardial apoptosis involving decreased hydroxyl radical production and Bax expression in an ischaemia/reperfusion rabbit heart.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Shinya Minatoguchi Research Topics

Disease

49Myocardial Infarction
09/2022 - 10/2002
36Infarction (Infarctions)
01/2022 - 10/2002
27Fibrosis (Cirrhosis)
07/2020 - 05/2005
21Ischemia
01/2016 - 10/2002
20Heart Failure
01/2022 - 08/2004
13Hypertension (High Blood Pressure)
07/2020 - 04/2005
12Coronary Artery Disease (Coronary Atherosclerosis)
03/2022 - 01/2004
9Cardiomyopathies (Cardiomyopathy)
01/2019 - 08/2004
8Hypertrophy
10/2019 - 07/2005
7Left Ventricular Dysfunction
01/2022 - 01/2004
7Reperfusion Injury
01/2020 - 12/2007
7Pathologic Constriction (Stenosis)
12/2015 - 07/2003
7Coronary Occlusion
09/2011 - 08/2002
6Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2019 - 03/2009
6Atrial Fibrillation
03/2018 - 01/2012
6Inflammation (Inflammations)
04/2015 - 09/2006
6Cicatrix (Scar)
03/2009 - 06/2004
5Cardiovascular Diseases (Cardiovascular Disease)
01/2022 - 12/2007
5Lung Neoplasms (Lung Cancer)
01/2019 - 03/2010
5Thrombosis (Thrombus)
12/2012 - 05/2002
5Ventricular Remodeling
10/2007 - 05/2003
4Heart Diseases (Heart Disease)
01/2019 - 02/2003
4Diabetes Mellitus
01/2019 - 05/2005
4Peripheral Arterial Disease
02/2016 - 09/2006
4Emphysema
12/2015 - 10/2006
4Coronary Disease (Coronary Heart Disease)
10/2015 - 04/2006
4Atherosclerosis
01/2015 - 09/2007
4Starvation
12/2012 - 05/2009
4Proteinuria
03/2010 - 10/2007
3Acute Coronary Syndrome
09/2022 - 05/2011
3Sclerosis
07/2020 - 12/2005
3Myocardial Ischemia (Ischemic Heart Diseases)
01/2020 - 12/2007
3Chronic Renal Insufficiency
04/2019 - 04/2016
3Type 2 Diabetes Mellitus (MODY)
01/2019 - 09/2002
3Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
01/2019 - 02/2003
3Hypoxia (Hypoxemia)
07/2015 - 08/2010
3Hyperplasia
07/2013 - 05/2002
3Pneumonia (Pneumonitis)
01/2012 - 01/2007
3Cardiomegaly (Heart Hypertrophy)
07/2011 - 02/2003

Drug/Important Bio-Agent (IBA)

15LipidsIBA
03/2022 - 05/2002
14Granulocyte Colony-Stimulating Factor (G-CSF)IBA
07/2015 - 06/2004
13Adenosine Triphosphate (ATP)IBA
12/2012 - 10/2002
8SaltsIBA
07/2020 - 06/2003
8NG-Nitroarginine Methyl Ester (L-NAME)IBA
12/2017 - 06/2003
8Nitric Oxide (Nitrogen Monoxide)FDA Link
12/2017 - 06/2003
8Doxorubicin (Adriamycin)FDA LinkGeneric
01/2016 - 01/2006
8Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
04/2015 - 08/2004
8ErythropoietinFDA Link
04/2013 - 01/2006
8Hydroxyl RadicalIBA
07/2009 - 06/2003
7Alprostadil (Muse)FDA LinkGeneric
01/2022 - 01/2018
7Indicators and Reagents (Reagents)IBA
12/2009 - 06/2003
6Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
01/2022 - 06/2003
6Pharmaceutical PreparationsIBA
01/2017 - 08/2008
6Proteins (Proteins, Gene)FDA Link
03/2012 - 09/2002
6KATP ChannelsIBA
10/2011 - 10/2002
5Glucagon-Like Peptide 1 (GLP 1)IBA
11/2019 - 06/2010
5Adenosine (Adenocard)FDA LinkGeneric
01/2019 - 01/2003
5Hypoglycemic Agents (Hypoglycemics)IBA
01/2019 - 05/2009
5Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
07/2015 - 12/2009
4Angiotensin Receptor AntagonistsIBA
01/2022 - 04/2007
4Prorenin ReceptorIBA
07/2020 - 01/2014
4miglitol (Glyset)FDA Link
11/2019 - 07/2004
4Glucose (Dextrose)FDA LinkGeneric
01/2017 - 10/2008
4candesartanIBA
09/2013 - 02/2008
4Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA
12/2012 - 05/2009
4Green Fluorescent ProteinsIBA
12/2012 - 05/2009
4Superoxides (Superoxide)IBA
01/2012 - 04/2007
4Antihypertensive Agents (Antihypertensives)IBA
04/2011 - 02/2006
4Nitric Oxide Synthase (NO Synthase)IBA
06/2010 - 06/2003
4Fas Ligand Protein (Fas Ligand)IBA
02/2010 - 09/2004
4Coloring Agents (Dyes)IBA
05/2009 - 06/2003
4mitochondrial K(ATP) channelIBA
05/2009 - 01/2004
4Nicorandil (SG 75)IBA
11/2007 - 07/2003
4Protein Kinase CIBA
10/2007 - 10/2002
45-hydroxydecanoic acidIBA
04/2007 - 10/2002
3Troponin IIBA
01/2022 - 01/2006
3Norepinephrine (Noradrenaline)FDA LinkGeneric
01/2022 - 01/2003
3Therapeutic UsesIBA
04/2019 - 07/2005
3Angiotensin IIIBA
11/2018 - 02/2008
3Carboplatin (JM8)FDA LinkGeneric
01/2017 - 03/2009
3oxidized low density lipoproteinIBA
01/2016 - 01/2014
3Pravastatin (Pravachol)FDA LinkGeneric
04/2015 - 06/2005
3pitavastatin (itavastatin)FDA Link
04/2015 - 02/2009
3ReninIBA
01/2015 - 05/2007
3Amlodipine (Norvasc)FDA LinkGeneric
09/2013 - 10/2007
3Valsartan (Vals)FDA Link
09/2013 - 04/2007
3Phosphotransferases (Kinase)IBA
12/2012 - 06/2004
3Cathepsin DIBA
12/2012 - 05/2009
3Pancreatic Elastase (Elastase)IBA
01/2012 - 10/2006
3Amino AcidsFDA Link
06/2011 - 05/2009
3HydrogelsIBA
04/2011 - 09/2008
3GelatinIBA
04/2011 - 09/2008

Therapy/Procedure

32Therapeutics
01/2022 - 08/2004
7Percutaneous Coronary Intervention
03/2022 - 01/2004
7Ligation
07/2015 - 02/2003
3Intravenous Administration
01/2020 - 02/2009
3Catheter Ablation
06/2018 - 09/2013
3Drug Therapy (Chemotherapy)
01/2017 - 07/2010
3Oral Administration
07/2016 - 06/2010
3Intraperitoneal Injections
01/2016 - 01/2006